The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

Citation
Haas, M., A. Loupy, C. Lefaucheur, C. Roufosse, D. Glotz, D. Seron, B. J. Nankivell, et al. 2018. “The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials.” American Journal of Transplantation 18 (2): 293-307. doi:10.1111/ajt.14625. http://dx.doi.org/10.1111/ajt.14625.

Published Version
doi:10.1111/ajt.14625

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:35014948

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://
M. Haas1 | A. Loupy2 | C. Lefaucheur3 | C. Roufosse4 | D. Glotz3 | D. Seron5 | B. J. Nankivell6 | P. F. Halloran7 | R. B. Colvin8 | Enver Akalin9 | N. Alachkar10 | S. Bagnasco11 | Y. Bouatou12 | J. U. Becker13 | L. D. Cornelli14 | J. P. Duong van Huyen2 | I. W. Gibson15 | Edward S. Kraus16 | R. B. Mannon17 | M. Naesens18 | V. Nickeleit19 | P. Nickerson20 | D. L. Segev21 | H. K. Singh19 | M. Stegall22 | P. Randhawa23 | L. Racusen11 | K. Solez24 | M. Mengel24

1Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA
2Paris Translational Research Center for Organ Transplantation, INSERM U970 and Necker Hospital, University Paris Descartes, Paris, France
3Paris Translational Research Center for Organ Transplantation and Department of Nephrology and Transplantation, Hopital Saint Louis, Université Paris VII and INSERM U 1160, Paris, France
4Department of Medicine, Imperial College London and North West London Pathology, London, UK
5Nephrology Department, Hospital Vall d’Hebron, Autonomous University of Barcelona, Barcelona, Spain
6Department of Renal Medicine, Westmead Hospital, Sydney, Australia
7Alberta Transplant Applied Genomics Centre, University of Alberta, Edmonton, Alberta, Canada
8Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
9Montefiore-Einstein Center for Transplantation, Montefiore Medical Center, Bronx, NY, USA
10Department of Medicine, Section of Nephrology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
11Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
12Division of Nephrology, Department of Medical Specialties, Geneva University Hospitals, Geneva, Switzerland
13Institute of Pathology, University Hospital of Cologne, Cologne, Germany
14Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
15Department of Pathology, University of Manitoba, Winnipeg, Canada
16Division of Nephrology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA
17Division of Nephrology, Department of Medicine, University of Alabama School of Medicine, Birmingham, AL, USA
18Department of Microbiology and Immunology, University of Leuven & Department of Nephrology, University Hospitals Leuven, Leuven, Belgium
19Division of Nephropathology, Department of Pathology and Laboratory Medicine, The University of North Carolina School of Medicine, Chapel Hill, NC, USA
20Department of Internal Medicine and Immunology, University of Manitoba, Winnipeg, Canada
21Department of Surgery, Johns Hopkins Medical Institutions, Baltimore, MD, USA
22Departments of Surgery and Immunology, Mayo Clinic, Rochester, MN, USA
23Division of Transplantation Pathology, Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA, USA
24Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Canada

**Abbreviations:** AMBR, antibody-mediated rejection; BCAR, biopsy-confirmed acute rejection; cg, Banff chronic glomerulopathy score; DSA, donor-specific antibody; DSAST, “DSA-specific” transcript set; EMA, European Medicines Agency; EM, electron microscopy; FDA, US Food and Drug Administration; FFPE, formalin-fixed paraffin-embedded; g, Banff glomerulitis score; IF, immunofluorescence; IFTA, interstitial fibrosis and tubular atrophy; i-IFTA, inflammation in areas of interstitial fibrosis and tubular atrophy; MVI, microvascular inflammation; ptc, Banff peritubular capillaritis score; PTCML, peritubular capillary basement membrane multilayering; STAR, Sensitization in Transplantation: Assessment of Risk; TCMR, T cell-mediated rejection; TG transplantation glomerulopathy

Mark Haas and Alexandre Loupy contributed equally to this report.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2017 The Authors. *American Journal of Transplantation* published by Wiley Periodicals, Inc. on behalf of The American Society of Transplantation and the American Society of Transplant Surgeons
The kidney sessions of the 2017 Banff Conference focused on 2 areas: clinical implications of inflammation in areas of interstitial fibrosis and tubular atrophy (i-IFTA) and its relationship to T cell–mediated rejection (TCMR), and the continued evolution of molecular diagnostics, particularly in the diagnosis of antibody-mediated rejection (ABMR). In confirmation of previous studies, it was independently demonstrated by 2 groups that i-IFTA is associated with reduced graft survival. Furthermore, these groups presented that i-IFTA, particularly when involving >25% of sclerotic cortex in association with tubulitis, is often a sequela of acute TCMR in association with underimmunosuppression. The classification was thus revised to include moderate i-IFTA plus moderate or severe tubulitis as diagnostic of chronic active TCMR. Other studies demonstrated that certain molecular classifiers improve diagnosis of ABMR beyond what is possible with histology, C4d, and detection of donor-specific antibodies (DSAs) and that both C4d and validated molecular assays can serve as potential alternatives and/or complements to DSAs in the diagnosis of ABMR. The Banff ABMR criteria are thus updated to include these alternatives. Finally, the present report paves the way for the Banff scheme to be part of an integrative approach for defining surrogate endpoints in next-generation clinical trials.

**KEYWORDS**
classification systems: Banff classification, kidney transplantation/nephrology, molecular biology, pathology/histopathology, rejection, translational research/science

**1 | INTRODUCTION**

The XIV Banff Conference for Allograft Pathology was held March 27-31, 2017, in Barcelona, Spain, in conjunction with the annual meeting of the Catalan Society of Transplantation. A total of 479 delegates from 23 countries attended the conference, including pathologists, immunologists, physicians, surgeons, and immunogeneticists. The main aim of the 2017 conference was to revisit the current diagnostic criteria for chronic T cell–mediated rejection (TCMR), especially the significance of inflammation in areas of interstitial fibrosis and tubular atrophy (i-IFTA). In addition, discussion related to the relevance and potential integration of molecular transplant diagnostics into the Banff classification was continued along the roadmap developed at the 2015 Banff meeting. This included an update of the criteria for assessing molecular features related to antibody-mediated tissue injury as a potential alternative/complement to donor-specific antibodies (DSAs) for diagnosing antibody-mediated rejection (ABMR). In alignment with ongoing efforts of the American Society of Transplantation (Transplant Therapeutics Consortium) and the American Society of Histocompatibility and Immunogenetics (STAR initiative [Sensitization in Transplantation: Assessment of Risk]), the Banff 2017 conference was preceded by a full-day premeeting on “New Endpoints for Next-Generation Clinical Trials” in which the current and future role of the Banff classification and unmet needs for the field with regard to surrogate endpoints were discussed. In addition, the meeting included as a standing item an update session on the ongoing activities of the Banff Working Groups, which is summarized in Table 1.

This meeting report focuses on the main outcomes from the Banff kidney sessions, and the resulting changes to the classification. The main conclusions from the 2017 Banff liver, heart, lung, pancreas, and vascularized composite allograft sessions will be published elsewhere. The next XV Banff meeting will be held jointly with the American Society of Histocompatibility and Immunogenetics in Pittsburgh, PA, September 23-27, 2019.

**2 | DEFINING ENDPOINTS IN KIDNEY TRANSPLANTATION FOR NEXT-GENERATION CLINICAL TRIALS: PLACE OF THE BANFF SCHEME AND COMBINED ENDPOINTS**

The approval of novel drugs in the field of kidney transplantation has been dampened by several factors. One of the explanations for the failure of trials testing new agents has been the success of the “gold standard” immunosuppression demonstrated in the Symphony study and on the other hand, the relative lack of success of new agents. The US Food and Drug Administration (FDA)/European Medicines Agency (EMA)-approved primary endpoints, such as 1-year graft and patient survivals, are irrelevant today for superiority trials, due to excellent graft and patient survival in the overall transplant populations (~95%) and are difficult to improve further. Designing studies with 5- or 10-year graft and patient survival as primary endpoints are unrealistic in terms of costs, especially as transplantation is a small field/market.

*Correspondence
Mark Haas and Alexandre Loupy
Email: mark.haas@cshs.org; alexandreloupy@gmail.com
with potentially repositionable drugs known already for their adverse reaction profiles. Acute rejection is also recognized as a primary endpoint for clinical trials in transplantation by health authorities, but TCMR and ABMR do not have the same impact on graft outcome. Furthermore, the transplant community and the industry aiming to introduce new agents are addressing these issues independently.

The Banff process has evolved from being a primarily pathology-driven group to a more comprehensive and multidisciplinary approach that includes relevant subject matter expertise from immunogeneticists, clinicians, and pathologists with the goal to establish and refine integrative diagnostic standards in transplantation. To accelerate the development of new immunosuppressive agents, Banff is currently working closely with regulatory agencies and international societies to define realistic and feasible endpoints and approaches for next-generation clinical trials. Various specialty societies and consortia have identified the unmet need for the validation of surrogate endpoints in order to evaluate responses to therapy and predict long-term kidney allograft outcomes. During the 2017 Banff premeeting, those new challenges were addressed with a specific focus on histologic, immunologic, and molecular endpoints.

2.1 | Histopathology as an endpoint

Rejection episodes confirmed by histology are recognized as the cornerstone of diagnosis and prognosis in kidney and transplantation pathology. However, the current FDA/EMA-approved surrogate histologic endpoint, biopsy-confirmed acute rejection (BCAR), is no longer reflecting current diagnostics in renal transplantation, where the impact of acute TCMR on outcome has declined. As an example, in the BENEFIT Study, BCAR was used as primary endpoint for non-inferiority, and there was more BCAR (TCMR) in the arm receiving belatacept (vs cyclosporine), but this did not lead to a higher rate of graft loss in the long term as shown by the BENEFIT-EXT study. To regain usefulness as primary endpoints for trials in kidney transplantation, histologic markers need to follow a validation process as outlined during the Banff meeting (Table 2A).

2.2 | Intragraft gene expression as an endpoint

In Table 2B, we listed our recommendations on best practices for molecular endpoints in clinical trials. Potential diagnostic and prognostic molecular endpoints and biomarkers are listed in Tables 3 and 4.

2.3 | Anti-HLA DSAs as an endpoint

To be a potential surrogate endpoint, anti-HLA DSAs have not only to be considered within the context of their potential limitations (titration rather than mean fluorescence intensity to reveal oversaturation) but also by integrating their properties (eg, complement activating capacity, IgG subclasses, cytotoxic effect). However, current shortcomings of DSA testing (variability in test methods, diagnostic threshold definitions, clinical significance standards) are known to limit its utility as a sole endpoint. Ongoing efforts of the STAR initiative are aiming to address these.

2.4 | Potential of innovative combined endpoints

The participants in the 2017 Banff premeeting support a path toward integrated diagnostic and prognostication systems by exploring opportunities provided by advanced data and applied statistics from the field of machine learning. To this end, the Banff group formed a new working group on surrogate endpoints aimed at fostering collaboration with other professional societies and regulatory agencies on the common goal to develop a path forward to successful next-generation multicenter trials and approval of novel drugs in solid organ transplantation.

3 | 2017 REVISIONS TO THE BANFF CLASSIFICATION

3.1 | T cell–mediated rejection

The Banff 2015 meeting report noted for the first time that chronic active TCMR may be manifest in the tubulointerstitial as well as in the vascular compartment. However, the current Banff classification does not provide specific criteria regarding how tubulointerstitial changes should be considered for diagnosing chronic active TCMR, although Banff consensus criteria for semiquantitatively scoring inflammation in areas of IFTA (i-IFTA) as a histologic lesion have been established. Although potential problems in scoring i-IFTA might be anticipated as scattered inflammatory cells are often seen in what might be considered by many pathologists to be bland fibrosis, the Paris group reported good agreement among 3 pathologists in grading i-IFTA according to the Banff 2015 criteria, with complete agreement between all 3 pathologists in 101 (67%) of 150 cases, and a κ value of 0.62.

The impact of i-IFTA on graft outcomes was first suggested by the finding of Mengel et al that total cortical inflammation (Banff ti score) was more predictive of graft loss than inflammation in nonsclerotic areas of cortex (Banff i score). Independently, the DeKAF study showed a strong association between the severity of i-IFTA and graft loss, far stronger than that of IFTA alone. Degrees of inflammation involving >25% of areas of cortex with IFTA (corresponding to Banff 2015 i-IFTA scores 2 and 3) were significantly associated with an increased risk of graft loss in multivariate models. These findings were independently validated by recent studies of Lefaucheur, Loupy, and coworkers and Nankivell et al. The amenability of i-IFTA to immunosuppressive therapy remains an important question, and findings of the DeKAF study showed that the effect of i-IFTA on graft survival was not significantly affected by treatment for concomitant acute TCMR. Still, data presented by the Paris group showed that i-IFTA is related to underimmunosuppression, and both this group and Nankivell et al found that i-IFTA is typically preceded by TCMR. Furthermore, the frequency of i-IFTA in protocol biopsy specimens has declined in the era of tacrolimus-based immunosuppression compared with that of cyclosporine-based immunosuppression. Taken together, these findings suggest that i-IFTA, at least in many instances, is related to chronic underimmunosuppression and thus can represent
### TABLE 1  Update on active Banff working groups

| Leaders                  | Issues to address                                                                                                                                                                                                                                                                                                                                 | Group progress/future plans                                                                                                                                                                                                                                                                                                                                 |
|--------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| TCMR                     | V. Nickeleit, P. Randhawa                                                                                                                                                                                                                                                                                                                                 | To this point compiled 81 cases of “pure” TCMR with complete clinical/pathologic data sets, and an additional 140 cases with incomplete data. More cases of “pure” TCMR with complete pathologic and clinical data for evidence-based analysis of TCMR/borderline thresholds are required; these cases need to have documented absence of DSA and sufficient follow-up. Survey among renal pathologists (including very experienced) revealed nonuniform application of current Banff TCMR cutoffs, consideration of non-Banff lesions in TCMR diagnosis, grading or nongrading of i-IFTA. See also discussion of i-IFTA scoring and clinical relevance for diagnosis of chronic active TCMR. |
| Sensitized               | L. Cornell, E. Kraus, S. Bagnasco, C. Schinstock, D. Dadhania                                                                                                                                                                                                                                                                                        | Survey regarding clinical practice related to highly sensitized patients indicates that:  
- Clinicians often fail to recognize chronic elements of ABMR (eg, cg >0)  
- Clinicians more likely to consider a diagnosis of chronic, active ABMR if C4d is negative, even if there is no TG, PTCBML, or IFTA  
- The term “acute” (in acute/active ABMR) is confusing to clinicians, and consequently it has been removed from the Banff classification—see Table 5  
- Further improve communication between pathologists and clinicians regarding reporting of biopsy findings in HS, including the presence of C4d-negative early ABMR                                                                                                                                                                                                 |
| Molecular                | M. Mengel, B. Sis                                                                                                                                                                                                                                                                                                                                    | Further data from experiences with gene expression analysis applied to FFPE tissue was presented:  
- the method can reproducibly be applied to almost any FFPE sample in different species  
- multicenter studies are under way or planned for applications in kidney, heart, pancreas, and lung transplantations                                                                                                                                                                                                                           |
| Electron microscopy      | C. Roufosse, H.K. Singh                                                                                                                                                                                                                                                                                                                             | A survey showed that current Banff guidelines do not provide enough detail regarding when to do EM, and that current guidelines are often not followed due to cost restrictions or limited access to EM Future studies will focus on:  
- How reversible is cg1a?  
- What is the prognostic significance of cg1a compared with that of overt TG?  
- Is there a level of PTCBML lower than that required to diagnose chronic active ABMR in Banff 2013, that is useful in the diagnosis of early chronic ABMR, and, if so, is this potentially reversible with treatment for ABMR?  
Goals:  
- To create a comprehensive teaching module for TG and PTCBML evaluation and guidelines for diagnosis of ultrastructural changes with a follow-up test using digital images  
- Multicenter validation of diagnostic criteria and final recommendations |
| TABLE 1 (Continued) | Leaders | Issues to address | Group progress/future plans |
|----------------------|---------|------------------|-----------------------------|
| **Thrombotic microangiopathy (TMA)** | M. Afrouzian, J. U. Becker, H. Liapis, S. Seshan | Establish uniform diagnostic criteria for TMA. Determine the frequency with which TMA occurs in renal allograft biopsy specimens. Determine if there are specific features of TMA in renal allografts that help resolve the differential diagnosis of the TMA when the cause is not readily apparent from clinical history, DSA/C4d, etc. | Survey of 26 centers showed TMA diagnosed in 5%-10% of biopsy specimens in 42% of centers, <5% in 35%, 10%-20% in 23% of centers. Focus future efforts on working with other groups (eg, KDIGO, ERKnet) in defining TMA uniformly in native and transplanted kidneys. Compare and contrast features of TMA in known cases of CNI-related TMA (from native kidneys of recipients of other solid organs), TMA in the setting of well-documented ABMR (DSA+, C4d), and recurrent aHUS to assess differences in morphologic and other (eg, laboratory, molecular) features between these that will be potentially useful in determining the most likely etiology in TMA cases where the latter is not clear. |
| **Recurrent glomerular disease** | N. Alachkar, S. Bagnasco | Establish pathologic guidelines for early recurrence of glomerular diseases, including FSGS, IgA nephropathy, and MPGN/C3GN. What are frequencies, clinical manifestations, and pathologic characteristics of recurrent/de novo glomerular disease? Can any of these predict recurrence and/or graft outcomes? Understand the pathologic changes of recurrent glomerular diseases occurring concurrently with rejection and other transplant-associated lesions. | Biopsy specimens are now collected from 5 centers and preliminary studies confirm IgA nephropathy and FSGS as the most prevalent recurring diseases. Future directions: Are there clinical and/or pathologic features of the native disease that predict likelihood of recurrence? Are there clinical and/or pathologic features of the recurrent disease in the allograft that predict graft loss? Which pathologic analyses (IF, EM, others) are needed for optimal and early diagnosis of recurrent disease? Is the apparent association of recurrent glomerular disease with acute rejection related to biopsy bias (ie incidental discovery of recurrent disease in biopsies done to r/o rejection), under-immunosuppression, or both? |
| **Surrogate endpoints (new working group)** | A. Loupy, B. Orandi | Respond to the unmet need raised by the FDA meeting held in Arlington in 2015: build a validated multicenter composite scoring system integrating histopathology with other relevant allograft biomarkers to predict long-term allograft outcome. | See summary of Banff pre-meeting “New Endpoints for Next Generation Clinical Trials” |
| **HIV+/HIV- renal transplants (new working group)** | S. Bagnasco | Are there specific issues/difficulties in diagnosing transplant-associated pathologic lesions (TCMR, ABMR, others and components of these) in the setting of concurrent HIV-associated pathology (related to the virus itself and to anti-retroviral therapy). Do the incidence, pathology, and therapeutic response of rejection in cases of HIV+/HIV+ renal transplantation differ from those with HIV-donor kidneys transplanted into HIV- recipients and into HIV+ recipients. If so, how are these differences manifest? Overall, develop a set of evidence-based guidelines for HIV+/HIV+ renal transplants. | Efforts are underway to standardize the histological assessment of HIV-associated nephropathies in native kidneys (eg, KDIGO). Any scoring of such lesions in transplants should follow the native kidney criteria. Subsequently transplant specific pathologies can be defined. Further efforts of this BWG will focus on working with the native kidney groups on standardizing the HIV-related pathology scoring. |
| **Banff rules and dissemination (new working group)** | J. U. Becker, C. Roufosse | Collation of contents of previous Banff reports in a central web-based, updatable repository including diagnostic parameters, definitions and rules. Elaboration of a minimum dataset and algorithms for application of Banff classification. | Finalisation of the collation of current content during a meeting in London, UK in September 2017. Preparation of a review manuscript with contents of previous Banff reports up to 2015. Incorporation of possible changes in Banff 2017 report to content for the web-based repository in 2018. |
Table 2  Banff recommendations on best practice for pathology and molecular endpoints in clinical trials

| A. Banff recommendations on best practices for pathology endpoints in clinical trials |
|-------------------------------------------|
| Pathologists to participate in the design and choice of endpoints |
| Panel of pathologists (3 optimal to avoid a tie) |
| Adjudication mechanism (how discordance between pathologists is addressed) |
| Whole slide digital images for centralized slide review |
| Auditable assessments (scoring that can be reviewed and audited externally) |
| Granular scoring (detailed phenotyping and lesions scoring considered for end-points) |
| Quantitate changes (use of continuous scores and percentages rather than semi-quantitative scoring) |
| Centralized processing of ancillary testing, eg IHC stains |

| B. Banff recommendations on best practices for molecular endpoints in clinical trials |
|-------------------------------------------|
| The primary effort should be on applying molecular studies to biopsies |
| Large Reference data sets should be well annotated |
| High reproducibility/replication of assays |
| Pathogenesis based transcript strategy appears useful and can be completed by classifier approaches (no single gene test is specific) |
| Centralized testing advantageous for multi-center trials molecular analysis |
| Proper methodological approaches are needed (for both assay performance and data analysis, ...) Adds statistical power, potentially reducing sample size and costs |
| Quality Assurance is mandatory (inter-laboratory, inter-platform and inter-assay reproducibility; development of standardized positive and negative controls and quantitative diagnostic reference standard) |

Chronic active TCMR. Inflammation in non-IFTA and IFTA areas can coexist in the same biopsy specimen. Such biopsy specimens should still be diagnosed as chronic active TCMR and not labeled acute plus chronic active TCMR, because the latter already addresses the acute/active component in the rejection process. In other words, a biopsy fulfilling the diagnostic criteria for chronic active TCMR should not be given a second diagnosis of Borderline or acute TCMR. However, biopsies with chronic active TCMR can have an additional diagnosis of ABMR. In general, i-IFTA likely reflects a response to wounding of injured nephrons and renal tissue, as shown by molecular studies showing that any progressing chronic kidney diseases are associated with increased expression of acute kidney injury transcripts. Thus, i-IFTA is the morphologic correlate of active injury, compared with IFTA with no inflammation, and predicts disease progression as part of an active injury process damaging the nephron and potentially warranting treatment.12,13

Clearly, i-IFTA is not a specific lesion, and adding i-IFTA by itself, even if moderate to severe, to the classification as diagnostic of chronic active TCMR does not appear warranted based on present data. It is well known that many other disease processes, including BK virus infection, pyelonephritis, ABMR, recurrent glomerulonephritis, and obstruction, may at some point present with i-IFTA. The nonspecificity of i-IFTA for rejection, proved by the fact that it occurs in native kidneys, was the main reason why i-IFTA and tubulitis in atrophic tubules was specifically excluded from the classification at the first Banff meeting. However, since 1991, immunosuppression has changed and graft survival improved with more patients presenting late posttransplantation with i-IFTA requiring differential diagnostic resolution to guide treatment. Based on the most recent data taking this evolution into account, i-IFTA is likely to be a manifestation of TCMR when associated with other features of ongoing T cell–mediated alloimmunity, such as tubulitis or a history of TCMR episodes in a patient, especially after excluding other diseases known to be associated with i-IFTA (eg, BK, ABMR, GN, obstruction). The study from the Paris group did show that i-IFTA was significantly correlated with the presence of tubulitis, in both scarred and nonscarred areas of the cortex.8 Thus, at present and to minimize overdiagnosis, tubulointerstitial lesions of chronic active TCMR have been added to the working classification (Table 5) as a combination of i-IFTA and tubulitis involving all but severely atrophic tubules, with moderately high thresholds for both (i-IFTA2–3; t2–3), a requirement for inflammation involving >25% of the total cortex present, and other differential diagnoses known to be associated with i-IFTA (eg, chronic pyelonephritis, BK nephropathy) being ruled out. Notably, Lefaucheur et al10 found that i-IFTA scores of 2 and 3, but not 1, as well as t2 and t3 tubulitis (but not t1) within areas of IFTA, excluding severely atrophic tubules, were associated with an increased rate of graft loss. This conservative approach has served the Banff group well in the past, with the introduction of C4d-negative ABMR.14 As with the latter (see later), future modifications will be considered as new data emerge from the Banff TCMR working group1 as well as from other, independent investigators. Key issues here concern the threshold values of individual histologic lesions needed to diagnose chronic active TCMR, whether the Banff i-IFTA score or ti score is more predictive of graft outcomes, association with nonadherence and underimmunosuppression, and possibly response to newer immunosuppressive therapy. Response to increase immunosuppressive therapies should be studied, as well as whether molecular parameters associated with TCMR15,16 may be useful in diagnosis.

At this point, there is no borderline or suspicious category for chronic active TCMR, particularly as this category within acute TCMR has proved to be troublesome for treating clinicians and even for pathologists to define (see Tables 3 and 4 of ref. 1). Furthermore, low levels of i-IFTA (i-IFTA 1) and mild tubulitis within foci of IFTA were not correlated with graft survival in the study of Lefaucheur et al.8 Figure 1 depicts lesions of chronic active TCMR grades IA (panels A and B) and IB (panels C and D). Both show extensive i-IFTA, with the main difference being the extent of tubulitis, being moderate (t2) in grade IA and severe (t3) in grade IB. Interstitial edema is present as well, although the latter is not a requirement for i-IFTA and the inflammation may be present in areas of denser, more-evolved fibrosis as is shown in Figure 2, which depicts 3 other biopsy specimens showing i-IFTA with varying densities of interstitial fibrosis and degrees of interstitial
inflammation, edema, and tubulitis using 3 different histologic stains (hematoxylin and eosin, periodic acid–Schiff, and Masson trichrome). The silver-stained sections in Figure 1 show tubulitis in mildly to moderately atrophic tubules (best evident in panels B and D), and both of these biopsy specimens also show some severely atrophic tubules. The latter tubules are defined by having a diameter <25% of that of unaffected or minimally affected tubules on the biopsy, often with an undifferentiated-appearing, cuboidal, or flattened epithelium (or, in some cases, even loss of epithelium with denudation of the tubular basement membrane). This definition of severely atrophic tubules also includes very small, endocrine-like tubules with very narrow lumens, although the basement membranes of the latter may not be thickened. Frequently, severely atrophic tubules will show tubulitis even if there is minimal accompanying interstitial inflammation; this is true even in native kidney biopsy specimens. Therefore, tubulitis in these tubules is presently considered not toward the diagnosis of chronic active TCMR (Table 5), although this point requires further study, which will be done by the TCMR working group. The interobserver reproducibility of pathologists to distinguish severely atrophic tubules from less atrophic ones will also need further testing, although encouraging results were reported by the Paris group.8 They reported a complete agreement rate between 3 pathologists of 72% and a x value of .58 in grading tubulitis in areas of IFTA excluding severely atrophic tubules, although the latter were not defined by a specific reduction in size.

3.2 | Antibody-mediated rejection

Several potential updates to the Banff 2015 criteria for ABMR were considered. The most important of these concerned potential alternatives to the DSA criterion in the diagnosis of ABMR. Evidence in support of incorporation into the classification of 2 such alternative markers, C4d and molecular ABMR assessment17–20 consisting of either a set of antibody-mediated tissue injury–associated genes, or a respective molecular classifier, was reviewed at the 2017 Banff conference and is summarized in the following section. In a postmeeting poll answered by 63 experts, incorporation of these markers into the Banff classification for ABMR was favored by a majority, and this is reflected in the revised criteria for the diagnosis of ABMR described in this 2017 revision (Table 5). As C4d positivity is now considered an alternative for DSA criterion in cases where DSA testing is not available or potentially false negative, all biopsy specimens showing at least focally positive C4d staining now fall into 1 of 3 diagnostic categories: active ABMR, chronic active ABMR, and C4d staining without histologic evidence of rejection (Table 5). The potentially confusing categories of “suspicous for active ABMR” and “suspicous for chronic active ABMR” are now eliminated. It should be stressed here that these new criteria allowing for the diagnosis of ABMR in the absence of detectable DSAs do not constitute recognition of “antibody-negative ABMR” in the sense that Banff 2013 first recognized C4d-negative ABMR. It is rather an acceptance of the fact that current DSA testing methods do not detect all antibodies that are potentially injurious to the allograft, including some non-HLA antibodies, and that using the alternative markers discussed next will allow us to diagnose and treat a small but significant subset of cases of ABMR where current DSA testing methods fall short or are not available. Finally, DSA testing remains strongly recommended in all cases with biopsy specimens meeting the morphologic criteria (criteria 1 and 2) for active or chronic active ABMR (Table 5), not only for ABMR diagnosis but also for risk stratification, evaluating the response to treatment and further patient monitoring. A minor consideration in the revised classification, discussed later, involves the removal of the word “acute” from “acute/active ABMR.”
TABLE 4 References for gene lists

| Reference | Description |
|-----------|-------------|
| ABMR—Adam³ | Multiplexed color-coded probe-based gene expression assessment for clinical molecular diagnostics in formalin-fixed paraffin-embedded human renal allograft tissue. Adam B, Afzali B, Dominy KM, Chapman E, Gill R, Hidalgo LG, Roufosse C, Sis B, Mengel M. Clin Transplant. 2016 Mar;30(3):295-305. |
| ABMR—Halloran | Molecular diagnosis of antibody-mediated rejection in human kidney transplants. Sellares J, Reeve J, Loupy A, Mengel M, Sis B, Skene A, de Freitas DG, Kreepala C, Hidalgo LG, Famulski KS, Halloran PF. Am J Transplant. 2013 Apr;13(4):971-83. |
| ABMR—Venner | The molecular landscape of antibody-mediated kidney transplant rejection: evidence for NK involvement through CD16a Fc receptors. Venner JM, Hidalgo LG, Famulski KS, Chang J, Halloran PF. Am J Transplant. 2015 May;15(5):1336-48. |
| ABMR—Roufosse | Use of quantitative real time polymerase chain reaction to assess gene transcripts associated with antibody-mediated rejection of kidney transplants. Dominy KM, Roufosse C, de Kort H, Willicombe M, Brookes P, Behnoorhas J, Petretto EG, Galliford J, Choi P, Taube D, Cook HT, Mclean AG. Transplantation. 2015 Sep;99(9):1891-8. |
| DSAST—Halloran (donor-specific antibody-associated transcripts) | NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: evidence for NK cell involvement in antibody-mediated rejection. Hidalgo LG, Sis B, Sellares J, Campbell PM, Mengel M, Eichege C, Chang J, Halloran PF. Am J Transplant. 2010 Aug;10(8):1812-22. |
| C5-Inh Responds—Lefaucheur/Loupy (complement component 5 inhibition treatment response associated transcripts) | Complement-activating anti-HLA antibodies in kidney transplantation: allograft gene expression profiling and response to treatment. J Am Soc Nephrol. 2017 Oct 17. Lefaucheur C, Viglietti D, Hidalgo LG, Ratner LE, Bagnasco SM, Batal I, Aubert O, Orandi BJ, Oppeneimer F, Bestard O, Rigotti P, Reisater AV, Kamar N, Lebranchu Y, Duong Van Huyen JP, Bruneval P, Giotz D, Legendre C, Empama JP, Jouven X, Segev DL, Montgomery RA, Zeevi A, Halloran PF, Loupy A. J Am Soc Nephrol. 2017 Oct 17. |
| TCMR—Sellares | Molecular diagnosis of T cell-mediated rejection in human kidney transplant biopsies. Reeve J, Sellares J, Mengel M, Sis B, Skene A, Hidalgo L, de Freitas DG, Famulski KS, Halloran PF. Am J Transplant. 2013 Mar;13(3):645-55. |
| TCMR—Halloran | Real Time Central Assessment of Kidney Transplant Indication Biopsies by Microarrays: The INTERCOMEX Study. Halloran PF, Reeve J, Akalin E, Aubert O, Bohmig GA, Brennan D, Bromberg J, Eichege C, Eskinard F, Gossell C, Duong Van Huyen JP, Gupta G, Lefaucheur C, Malone A, Mannon RB, Seron D, Sellares J, Weir M, Loupy A. J Am Transplant. 2011 Apr;21(1):208-21. |
| TCMR—Venner | Molecular landscape of T cell-mediated rejection in human kidney transplants: prominence of CTLA4 and PD ligands. Venner JM, Famulski KS, Badr D, Hidalgo LG, Chang J, Halloran PF. Am J Transplant. 2014 Nov;14(11):2565-76. |
| Common rejection module (CRM)—Sarwal | A common rejection module (CRM) for acute rejection across multiple organs identifies novel therapeutics for organ transplantation. Khatri P, Roeder S, Kimura N, De Vusser K, Morgan AA, Gong Y, Fischbein MP, Robbins RC, Naesens M, Butte AJ, Sarwal MM. J Exp Med. 2013 Oct 21;210(11):2205-21. |
| Constant of rejection—National Institutes of Health | The immunologic constant of rejection. Wang E, Worscchek A, Marincon FM. Trends Immunol. 2008 Jun;29(6):256-62. |
| Exhaustion—Wherry | Molecular and cellular insights into T cell exhaustion. Wherry EJ, Kurachi M. Nat Rev Immunol. 2015 Aug;15(8):486-99. |
| Tolerance (blood)—Rebollo-Mesa | Biomarkers of tolerance in kidney transplantation: are we predicting tolerance or response to immunosuppressive treatment? Rebollo-Mesa I, Nova-Lamperti E, Mobillo P, Rungllall M, Christakoudi S, Norris S, Smallcombe N, Kamra Y, Hilton R. Indices of Tolerance EU Consortium, Bhandari S, Baker R, Berglund D, Carr S, Game D, Griffin S, Kala PA, Lewis R, Mark PB, Marks S, Macphee I, McKane W, Mohaupt MG, Parajajasingam R, Kon SP, Seron D, Sinha MD, Tucker B, Viklicky O, Lecherl RI, Lord GM, Hernandez-Fuentes MP. Am J Transplant. 2010 Aug;10(8):1812-22. |
| GoCar—O’Connell (Genomics of Chronic Allograft Rejection study) | Biopsy transcriptome expression profiling to identify kidney transplants at risk of chronic injury: a multicentre, prospective study O’Connell PJ, Zhang W, Menon MC, Yi Z, Schröppel B, Gallon L, Luan Y, Rosales IA, Ge Y, Losic B, Xi C, Woytovich C, Keung KL, Wei C, Greene I, Overbery J, Bagiella E, Najafian N, Samaniego M, Djamali A, Alexander SI, Nankivell BJ, Chapman JR, Smith RN, Colvin R, Murphy B. Lancet. 2016 Sep 3;388(10048):983-93. |
| CADI progression—Menon (chronic allograft damage index associated transcripts) | Intronic locus determines SHROOM3 expression and potentiates renal allograft fibrosis. Menon MC, Chuang PY, Li Z, Wei C, Zhang W, Luan Y, Yi Z, Xiong H, Woytovich C, Greene I, Overbery J, Rosales I, Bagiella E, Chen R, Ma M, Li L, Ding W, Djamali A, Saminego M, O’Connell PJ, Gallon L, Colvin R, Schroppel B, He JC, Murphy B. J Clin Invest. 2015 Jan;125(1):208-21. |
| AKI—Einecke (acute kidney injury associated transcripts) | Molecular phenotypes of acute kidney injury in kidney transplants. Famulski KS, de Freitas DG, Kreepala C, Chang J, Sellares J, Sis B, Einecke G, Mengel M, Reeve J, Halloran PF. J Am Soc Nephrol. 2012 May;23(5):948-58. |
| eGFR later—Vitalone (estimated glomerular filtration rate associated transcripts) | Transcriptional profiling of belatacept and calcineurin inhibitor therapy in renal allograft recipients. Vitalone MJ, Ganguly B, Hsieh S, Latek R, Kubkolas EJ, Townsend R, Sarwal MM. Am J Transplant. 2014 Aug;14(8):1912-21. |

(Continues)
3.3 Alternatives to the DSA criterion in ABMR diagnosis

Compared with the previous (2007) Banff classification for ABMR, in which peritubular capillary C4d staining was required in addition to microvascular inflammation (MVI; glomerulitis and/or peritubular capillaritis) and DSAs for the diagnosis of active ABMR, the Banff 2013 classification, which introduced C4d-negative ABMR, has a higher sensitivity for ABMR diagnosis and an improved association of ABMR diagnosis with graft outcome. Furthermore, molecular studies of Gupta et al. strongly validated the MVI sum score of (g + ptc) ≥ 2 required for diagnosis of ABMR by Banff 2013. Still, MVI, even with (g + ptc) scores of ≥ 2 and as high as 5, is not specific for ABMR; and Sis et al. found that 11% of patients with biopsy specimens showing (g + ptc) = 5 were DSA negative. Nevertheless, MVI remains strongly associated with graft outcomes and a

**TABLE 4** (Continued)

| Mast cells—Mengel (mast cell transcripts associated with IFTA) | Molecular correlates of scarring in kidney transplants: the emergence of mast cell transcripts. Mengel M, Reeve J, Bunnag S, Einecke G, Sis B, Mueller T, Kaplan B, Halloran PF. Am J Transplant. 2009 Jan;9(1):169-78. |
|---|---|
| Plasma cell—Einecke (plasma cell–associated transcripts) | Expression of B cell and immunoglobulin transcripts is a feature of inflammation in late allografts. Einecke G, Reeve J, Mengel M, Sis B, Bunnag S, Mueller TF, Halloran PF. Am J Transplant. 2008 Jul;8(7):1434-43. |
| TOLs—Colvin (tolerance-associated transcripts) | RNA expression profiling of non-human primate renal allograft rejection identifies tolerance. Smith RN, Matsunami M, Adam BA, Rosales IA, Oura T, Cosimi AB, Kawai T, Mengel M, Colvin RB. Am J Transplant 2017 In press. |
| Virus (virus-specific transcripts: BK, cytomegalovirus, Epstein–Barr virus) | Unpublished |

ABMR, antibody-mediated rejection; TCMR, T cell–mediated rejection.

*Also contains housekeeping genes.

**FIGURE 1** Representative cases of chronic active T cell–mediated rejection, grades 1A (A, B) and 1B (C, D). Each biopsy specimen shows widespread interstitial inflammation (mainly lymphocytes in A and B; lymphocytes with plasma cells in C and D) with accompanying interstitial edema in areas of the cortex with interstitial fibrosis and tubular atrophy (i-IFTA score 3). Both biopsy specimens also show tubulitis involving tubules with mild to moderate atrophic changes; this tubulitis is moderate (t2) in A and B and severe (t3) in C and D. There was also mild tubulitis (t1) in nonatrophic tubules in both biopsy specimens, and each specimen also had a total inflammation (ti) score of 2, although this cannot be determined from the photomicrographs. While both biopsy specimens show considerable edema associated with the inflammation, there is also interstitial fibrosis in these areas as is most evident from the darker staining areas of the interstitium in B and D. The yellow arrows indicate tubules with tubulitis; the tubules so indicated are the same tubules in the low-power and corresponding high-power photomicrographs (A, B; C, D). Jones methenamine silver stain; original magnification 100× (A, C) or 400× (B, D; scale bars in A and C indicate 50 µm)
problem with clinical application of the Banff 2013/2015 criteria remains what should be done in cases where there are no detectable DSAs but a biopsy specimen otherwise meeting criteria for ABMR (MVI score ≥1 and C4d-positive; MVI score ≥2 and C4d negative). In such instances, testing for non-HLA antibodies (eg, anti-angiotensin type 1 receptor) is strongly advised, although such testing is not done at all centers and the clinical implications of such antibodies are not completely understood. While the limited sensitivity of C4d in the diagnosis of ABMR is well recognized and led to the incorporation of C4d-negative ABMR into the Banff classification in 2013, multiple studies have shown that C4d staining in peritubular capillaries by immunofluorescence (IF) on frozen sections or immunoperoxidase on paraffin sections has a very high (>90%) specificity for the presence of DSAs if positive.\textsuperscript{26-28} False-positive C4d staining in peritubular capillaries was not seen in studies of native renal biopsy specimens or preimplantation biopsy specimens of donor kidneys.\textsuperscript{29,30} Accordingly, it was agreed that C4d staining in at least 10% of peritubular capillaries (C4d2 or C4d3) by IF on frozen sections or in any peritubular capillaries by immunoperoxidase on paraffin sections (C4d score >0) should be regarded as sufficient for the diagnosis of ABMR in the presence of MVI (ie, meeting criterion 3 of the classification), regardless of whether detectable DSAs are present (Table 5).

We also considered possible molecular alternatives to the DSA criterion. Molecular markers, in the form of those associated with endothelial injury, were first introduced into criterion 2 of the
**TABLE 5** Revised Banff 2017 classification of antibody-mediated rejection (ABMR) and T cell–mediated rejection (TCMR) in renal allografts: revisions highlighted in boldface type

| Category 1: Normal biopsy or nonspecific changes |
|------------------------------------------------|

| Category 2: Antibody-mediated changes |
|---------------------------------------|

**Active ABMR:** all 3 criteria must be met for diagnosis

1. Histologic evidence of acute tissue injury, including 1 or more of the following:
   - Microvascular inflammation (g > 0 and/or ptc > 0), in the absence of recurrent or de novo glomerulonephritis, although in the presence of acute TCMR, borderline infiltrate, or infection, ptc ≥ 1 alone is not sufficient and g must be ≥ 1
   - Intimal or transmural arteritis (v > 0)\(^1\)
   - Acute thrombotic microangiopathy, in the absence of any other cause
   - Acute tubular injury, in the absence of any other apparent cause

2. Evidence of current/recent antibody interaction with vascular endothelium, including 1 or more of the following:
   - Linear C4d staining in peritubular capillaries (C4d2 or C4d3 by IF on frozen sections, or C4d > 0 by IHC on paraffin sections)
   - At least moderate microvascular inflammation ([g + ptc] ≥ 2) in the absence of recurrent or de novo glomerulonephritis, although in the presence of acute TCMR, borderline infiltrate, or infection, ptc ≥ 2 alone is not sufficient and g must be ≥ 1

3. Serologic evidence of donor-specific antibodies (DSA to HLA or other antigens). C4d staining or expression of validated transcripts/classifiers as noted above in criterion 2 may substitute for DSA; however thorough DSA testing, including testing for non-HLA antibodies if HLA antibody testing is negative, is strongly advised whenever criteria 1 and 2 are met

**Chronic active ABMR:** all 3 criteria must be met for diagnosis\(^2\)

1. Morphologic evidence of chronic tissue injury, including 1 or more of the following:
   - Transplant glomerulopathy (cg >0) if no evidence of chronic TMA or chronic recurrent/de novo glomerulonephritis; includes changes evident by electron microscopy (EM) alone (cg1a)
   - Severe peritubular capillary basement membrane multilayering (requires EM)\(^3\)
   - Arterial intimal fibrosis of new onset, excluding other causes; leukocytes within the sclerotic intima favor chronic ABMR if there is no prior history of TCMR, but are not required

2. Identical to criterion 2 for active ABMR, above

3. Identical to criterion 3 for active ABMR, above, including strong recommendation for DSA testing whenever criteria 1 and 2 are met

**C4d Staining without Evidence of Rejection:** all 4 features must be present for diagnosis\(^4\)

1. Linear C4d staining in peritubular capillaries (C4d2 or C4d3 by IF on frozen sections, or C4d>0 by IHC on paraffin sections)

2. Criterion 1 for active or chronic, active ABMR not met

3. No molecular evidence for ABMR as in criterion 2 for active and chronic, active ABMR

4. No acute or chronic active TCMR, or borderline changes

| Category 3: Borderline changes |
|-------------------------------|

**Suspicious (Borderline) for acute TCMR**

Foci of tubulitis (t > 0) with minor interstitial inflammation (i0 or i1), or moderate-severe interstitial inflammation (i2 or i3) with mild (t1) tubulitis; retaining the i1 threshold for borderline with t > 0 is permitted although this must be made transparent in reports and publications

| Category 4: TCMR |
|------------------|

**Acute TCMR**

| Grade IA |
|----------|
| Interstitial inflammation involving >25% of nonsclerotic cortical parenchyma (i2 or i3) with moderate tubulitis (t2) involving 1 or more tubules, not including tubules that are severely atrophic\(^5\) |

| Grade IB |
|----------|
| Interstitial inflammation involving >25% of nonsclerotic cortical parenchyma (i2 or i3) with severe tubulitis (t3) involving 1 or more tubules, not including tubules that are severely atrophic\(^5\) |

| Grade IIA\(^1\) |
|-----------------|
| Mild to moderate intimal arteritis (v1), with or without interstitial inflammation and/or tubulitis |

| Grade IIB\(^1\) |
|-----------------|
| Severe intimal arteritis (v2), with or without interstitial inflammation and/or tubulitis |

| Grade III\(^1\) |
|-----------------|
| Transmural arteritis and/or arterial fibrinoid necrosis of medial smooth muscle with accompanying mononuclear cell intimal arteritis (v3), with or without interstitial inflammation and/or tubulitis |

(Continues)
TABLE 5 (Continued)

| Grade   | Description                                                                 |
|---------|-----------------------------------------------------------------------------|
| Grade IA | Interstitial inflammation involving >25% of the total cortex (ti score 2 or 3) and >25% of the sclerotic cortical parenchyma (i-IFTA score 2 or 3) with moderate tubulitis (t2) involving 1 or more tubules, not including severely atrophic tubules; other known causes of i-IFTA should be ruled out |
| Grade IB | Interstitial inflammation involving >25% of the total cortex (ti score 2 or 3) and >25% of the sclerotic cortical parenchyma (i-IFTA score 2 or 3) with severe tubulitis (t3) involving 1 or more tubules, not including severely atrophic tubules; other known causes of i-IFTA should be ruled out |
| Grade II1 | Chronic allograft arteriopathy (arterial intimal fibrosis with mononuclear cell inflammation in fibrosis and formation of neointima) |

Updates from Banff 20151 are indicated in boldface type.

1It should be noted that these arterial lesions may be indicative of ABMR, TCMR, or mixed ABMR/TCMR. "v" lesions and chronic allograft arteriopathy are only scored in arteries having a continuous media with ≥2 smooth muscle layers.

2Lesions of chronic active ABMR can range from primarily active lesions with early transplant glomerulopathy (TG) evident only by EM (cg1a) to those with advanced TG and other chronic changes in addition to active microvascular inflammation. For biopsy specimens showing TG and/or peritubular capillary basement membrane multilayering in the absence of evidence of current/recent antibody interaction with the endothelium (criterion 2) but with a prior documented diagnosis of active or chronic active ABMR or documented prior evidence of DSA, the term “chronic ABMR” should be applied.

3Indicates 7 layers in 1 cortical peritubular capillary and ≥5 in 2 additional capillaries, avoiding portions cut tangentially.

4The clinical significance of these findings may be quite different in grafts exposed to anti-blood group antibodies (ABO-incompatible allografts), where they do not appear to be injurious to the graft and may represent accommodation. However, with anti-HLA antibodies, such lesions may progress to chronic ABMR, and more outcome data are needed.

5A severely atrophic tubule is defined as one with each of the following 3 features: a diameter <25% of that of unaffected or minimally affected tubules on the biopsy, an undifferentiated-appearing, cuboidal or flattened epithelium, and pronounced wrinkling and/or thickening of the tubular basement membrane.

ABMR classification in Banff 2013.14 Since that time, combinations of transcripts have been introduced with far greater specificity for ABMR,17-20 although these molecular tests admittedly still have limitations and are not yet approved as diagnostic tests by regulatory bodies. Hidalgo et al31 introduced a "DSA-specific" transcript set (DSASTs) of mRNAs differentially expressed in biopsy specimens from DSA-positive and DSA-negative patients, excluding those differentially expressed in rejecting versus nonrejecting biopsy specimens, although these studies showed DSASTs to be more of a marker for ABMR than for the presence of DSAs.31 A more specific molecular marker for ABMR is the ABMR classifier,17-20 consisting of 30 nonredundant probes, selected from comparisons between biopsy specimens with versus those without histologic changes of ABMR. Data from Loupy et al19 showed that adding the results of the ABMR classifier to histologic findings significantly improved their ability to diagnose ABMR, independently from C4d and DSA. Therefore, despite the limitations noted, it was thought that this classifier or a related gene set could potentially be used to satisfy criterion 3 in the diagnosis of ABMR, similar to C4d (Table 5). It should be stressed that for this to be done at any given center, the cut-off value of such molecular assessment in the diagnosis of ABMR must be independently validated at each center at this point in time. With technologies becoming available to derive the molecular assessment (classifier or gene set) from formalin-fixed paraffin-embedded (FFPE) routine biopsy specimens,32,33 multicenter validation should become feasible in the near future through collaborative efforts of the ongoing Banff working groups (Table 1).

3.4 | Removal of the term “acute” from “acute/active ABMR”

In Table 2 of the 2013 Banff Classification,14 it is noted in a footnote that lesions classified as acute/active ABMR may be clinically acute, smoldering, or subclinical; this qualifier was also maintained in the 2015 revision.1 Thus, the use of the word “acute” in the term “acute/active ABMR” can be misleading, and it was elected to simply refer to lesions of ABMR with microvascular injury and evidence of current or recent antibody interaction with graft endothelium but without morphologic evidence of chronic vascular injury (transplant glomerulopathy [TG], peritubular capillary basement membrane multilayering [PTCBML], new-onset arterial intimal fibrosis [cv]), simply as active ABMR, keeping the footnote from Banff 2013 (Table 5). A majority (62%) of meeting attendees responding to the survey agreed. However, the rationale for this change goes beyond simply clarifying terminology and also considers the likelihood that there are multiple clinicopathologic forms of active ABMR. At a minimum, these include true acute ABMR, typically presenting with acute graft dysfunction in highly sensitized graft recipients having a memory humoral response, presenting early posttransplantation without chronic damage to the
TABLE 6  Recommended indications for use of molecular diagnostics in renal allograft biopsy diagnosis

| Histology/Banff scores/serology | Differential diagnosis | Possible molecular test |
|---------------------------------|------------------------|-------------------------|
| Mild MVI (g + ptc = 1) C4d negative, DSA positive | ABMR vs no ABMR | ABMR classifier17,40 DSAST31,41 |
| Moderate to severe peritubular capillaritis (ptc ≥ 2) No glomerulitis (g = 0) TCMR or borderline C4d negative, DSA positive | Pure TCMR/borderline vs mixed ABMR + TCMR/borderline | ABMR classifier17,40 DSAST31,41 |
| Moderate to severe MVI (g + ptc ≥ 2) C4d negative No identifiable anti-HLA DSA, ± non-HLA antibody | ABMR vs no ABMR | ABMR classifier17,40 DSAST31,41 |
| No MVI (g + ptc = 0) C4d positive, ± DSA ABO compatible | ABMR vs no ABMR | ABMR classifier17,40 DSAST31,41 |
| MVI (g + ptc > 0); C4d positive no identifiable anti-HLA DSA ABO incompatible | ABMR vs no ABMR | ABMR classifier17,40 DSAST31,41 |
| TG (cg > 0) No or mild MVI (g + ptc ≤ 1) C4d negative, DSA positive | Purely chronic ABMR or no ABMR vs chronic active ABMR | ABMR classifier17,40 DSAST31,41 |
| Borderline infiltrate | TCMR vs no TCMR | TCMR classifier42,43 |
| Isolated arteritis (no MVI or TCMR) C4d negative, ± DSA | TCMR vs no TCMR | TCMR classifier42,43 |

ABMR, antibody-mediated rejection; ABO, blood group antigens; cg, Banff chronic glomerulopathy score; DSA, donor-specific antibody; DSAST, donor-specific antibody specific transcript; g, Banff glomerulitis score; MVI, microvascular inflammation; ptc, Banff peritubular capillaritis score; TCMR, T cell-mediated rejection; TG, transplant glomerulopathy.

allograft; smoldering active ABMR, which may be diagnosed on surveillance or indication biopsy specimens in patients who most often have low-level DSAs (de novo or persistent/recurrent); and chronic active ABMR, which most often represents a continuum of the smoldering form should the latter not be diagnosed and treated in a timely manner, frequently in patients with limited compliance. In contrast with true acute ABMR, which can often be reversed by a combination of current, standard-of-care treatments aimed primarily at removing DSAs (eg, plasmapheresis, rituximab, intravenous immunoglobulin).34,35 smoldering active ABMR should be a major focus for future clinical trials of novel agents designed to treat active ABMR and prevent de novo or progressing TG by mechanisms other than (or in addition to) DSA removal. In summary, the word “active” in the pathology report indicates ongoing disease activity highlighted by MVI with or without concomitant chronic remodeling (TG, PTCBML, IFTA, cv) of the allograft.

3.5  Recommendations for use of molecular diagnostics

Molecular diagnostics were first introduced into the Banff classification in 2013,14 although this was limited to ABMR and its introduction was as much to encourage development of more specific and more universally applicable molecular tests as to be used in diagnosing ABMR at that time. That former goal has in fact come to fruition, and multiple groups in North America and Europe are now applying molecular diagnostics in analyzing renal allograft biopsy specimens18-20—as summarized in Tables 3 and 4. Just as the 2013 Banff meeting report14 put forth recommendations regarding taking a sample of tissue from renal allograft biopsies for electron microscopy (EM) and guidelines for performing EM to detect early changes of transplant glomerulopathy (cg1a), it is now appropriate to recommend sampling of biopsy tissue for molecular studies and to provide guidelines for when such studies are likely to be helpful diagnostically (Table 6). The latter specifically include situations where a combination of histologic, immunohistologic, and serologic data remain equivocal for diagnosis of ABMR, such as when the biopsy shows microvascular inflammation (g + ptc ≥ 2) but no C4d and there are no detectable DSAs; in biopsy specimens of ABO-incompatible allografts showing (g + ptc ≥ 2) and where a positive C4d is not helpful diagnostically;36; and in biopsy specimens of ABO-compatible grafts where there is C4d positivity and DSA but no histologic evidence of rejection. In addition, testing for transcript sets strongly associated with TCMR15,16,18,20 may also prove useful in differentiating borderline infiltrates likely to lead to development of overt TCMR and/or graft fibrosis from those that are not, as well as evaluating...
the thresholds values for chronic active TCMR introduced in this report (Table 5).

It should be noted that at this point no specific Banff recommendations are given regarding which molecular classifiers/transcript sets should be tested for or the platform(s) used to assess gene expression. This includes the decision whether to perform molecular studies on freshly sampled tissue or FFPE, the latter having the advantage of being done on the same tissue used for routine histology but with possible reduced sensitivity due to RNA degradation during processing. In all cases, molecular analyses need to be validated in any individual laboratory performing such testing, and gene expression thresholds significantly associated with ABMR, TCMR, or other lesions may well be different in different laboratories using the same transcript sets and platforms. As mentioned, because there are no specific lesions for ABMR/TCMR, no specific gene would be per se relevant for discriminating these diseases. A holistic molecular approach using machine learning and classifiers has been done in recent years and has provided valuable information for improving the classification and prognostic assessment of rejection.  

As discussed, the changes made to the Banff classification in 2013 stimulated many studies that largely validated those changes but also led to additional modification of the classification presented in the 2015 meeting report and here. Similarly, it is anticipated that the changes and recommendations made in this meeting report will serve as a stimulus for studies testing the validity of the revised diagnostic criteria for TCMR and ABMR with respect to predicting patient outcomes, as well as studies directly applying molecular diagnostics in the clinical setting along the path toward molecular consensus described in the 2015 Banff meeting report. The ultimate goals are not only to improve our ability to predict graft outcomes but also to better guide therapy, including in those cases where histology and serology alone cannot optimally do so, leading to improved patient outcomes compared with the current standard of care.

ACKNOWLEDGMENTS

We would like to acknowledge the instrumental support from the Roche Organ Transplantation Research Foundation Grant 608390948 awarded to Dr Kim Solez, which allowed establishment of the Banff Foundation for Allograft Pathology. The joint 2017 Banff and Catalan Transplant Society meeting acknowledges the receipt of sponsorship from Astellas, Chiesi, Novartis, One Lambda, Shire, Renal Pathology Society, American Society of Transplantation, Wiley, and Qiagen.

DISCLOSURE

Enver Akalin, Nada Alachkar, Serena Bagnasco, Jan Ulrich Becker, Robert Colvin, Yassine Bouatou, Lynn Cornell, Jean Paul Duong van Huyen, Ian Gibson, Denis Glotz, Ed Kraus, Roslyn Mannon, Maarten Naesens, Brian Nankivel, Volker Nickeleit, Lorraine Racusen, Parmjeet Randhawa, Candice Roufosse, Dorry Segev, Daniel Seron, Harsharan Singh, Kim Solez, Mark Stiegall had nothing to disclose. Carmen Lefaucheur and Alexandre Loupy received honoraria from Astellas and CSL Behring. They also received travel grants from ThermoFischer and Chiesi. Mark Haas serves as a paid consultant on pathology adjudication committees for two industry-sponsored clinical trials: Shire ViroPharma – Treatment of Acute Antibody-Mediated Rejection and AstraZeneca – Treatment of Proliferative Lupus Nephritis Philip F Halloran has shares in Transcriptome Sciences Inc (TYI), a University of Alberta spin-off company dedicated to developing molecular diagnostic solutions. Michael Mengel, research funding and honorarium from Shire Inc. Peter Nickerson, Consultant for Astellas Pharma and Vitaeris Inc.

ORCID

P. F. Halloran http://orcid.org/0000-0003-1371-1947
Y. Bouatou http://orcid.org/0000-0003-3697-3886

REFERENCES

1. Loupy A, Haas M, Solez K, et al. The Banff 2015 Kidney Meeting Report: current challenges in rejection classification and prospects for adopting molecular pathology. Am J Transplant. 2017;17(1):28-41.
2. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007;357(25):2562-2575.
3. O’Connell PJ, Kuypers DR, Mannon RB, et al. Clinical trials for immunosuppression in transplantation: the case for reform and change in direction. Transplantation. 2017;101(7):1527-1534.
4. Stiegall MD, Morris RE, Alloway RR, Mannon RB. Developing new immunosuppression for the next generation of transplant recipients: the path forward. Am J Transplant. 2016;16(4):1094-1101.
5. Vincenti F, Rostaing L, Grinyo J, et al. Belatacept and long-term outcomes in kidney transplantation. N Engl J Med. 2016;374(4):333-343.
6. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant. 2010;10(3):535-546.
7. Hart Y, Sheftel H, Hauser J, et al. Inferring biological tasks using Pareto analysis of high-dimensional data. Nat Methods. 2015;12(3):233-235, 3 p following 5.
8. Lefaucheur C, Gosset C, Rabant M, et al. T cell-mediated rejection as a major determinant of inflammation in scarred areas in kidney transplant recipients. Am J Transplant. 2017. https://doi.org/10.1111/ajt.14565.
9. Mengel M, Reeve J, Bunnag S, et al. Scoring total inflammation is superior to the current Banff inflammation score in predicting outcome and the degree of molecular disturbance in renal allografts. Am J Transplant. 2009;9(8):1859-1867.
10. Mannon RB, Matas AJ, Grande J, et al. Inflammation in areas of tubular atrophy in kidney allograft biopsies: a potent predictor of allograft failure. Am J Transplant. 2010;10(9):2066-2073.
11. Nankivel B, Shingde M, Keung K, et al. The causes, significance, and consequences of inflammatory fibrosis in kidney transplantation: the Banff i-IFTA lesion. Am J Transplant. 2018. https://doi.org/10.1111/ajt.14609.
12. Venner JM, Famulski KS, Reeve J, Chang J, Halloran PF. Relationships among injury, fibrosis, and time in human kidney transplants. JCI Insight. 2016;1(11):e85323.
13. Famulski KS, Reeve J, de Freitas DG, Kreepala C, Chang J, Halloran PF. Kidney transplants with progressing chronic diseases express high levels of acute kidney injury transcripts. Am J Transplant. 2013;13(3):634-644.
14. Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: inclusion of C4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant. 2014;14:272-283.
15. Reeve J, Sellares J, Mengel M, et al. Molecular diagnosis of T cell-mediated rejection in human kidneys. Am J Transplant. 2013;13:645-655.
16. Halloran PF, Reeve J, Akalin E, et al. Real time central assessment of kidney transplant indication biopsies by microarrays: the INTERCOMEX study. Am J Transplant. 2017;17:2851-2862.
17. Sellares J, Reeve J, Loupy A, et al. Molecular diagnosis of antibody-mediated rejection in human kidney transplants. Am J Transplant. 2013;13:971-983.
18. Halloran PF, Chang J, Famulski K, et al. Disappearance of T cell-mediated rejection despite continued antibody-mediated rejection in late kidney transplant recipients. J Am Soc Nephrol. 2015;26:1711-1720.
19. Loupy A, Lefaucheur C, Verrnery D, et al. Molecular microscope strategy to improve risk stratification in early antibody-mediated kidney allograft rejection. Am J Transplant. 2014;14:2267-2277.
20. Halloran PF, Venner JM, Famulski KS. Comprehensive analysis of transcript changes associated with allograft rejection: combining universal and selective features. Am J Transplant. 2017;17:1754-1769.
21. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant. 2008;8:753-760.
22. DeSerres S, Noel R, Cote I, et al. 2013 Banff criteria for chronic active antibody-mediated rejection: assessment in a real life setting. Am J Transplant. 2016;16:1516-1525.
23. Gupta A, O’Broin P, Bao Y, et al. Clinical and molecular significance of microvascular inflammation in transplant kidney biopsies. Kidney Int. 2016;89:217-225.
24. Sis B, Jhangri GS, Riopel J, et al. A new diagnostic algorithm for antibody-mediated microcirculation inflammation in kidney transplants. Am J Transplant. 2012;12:1168-1179.
25. de Kort H, Willicomb M, Brooks P, et al. Microcirculation inflammation associates with outcome in renal transplant patients with de novo donor-specific antibodies. Am J Transplant. 2013;13:485-492.
26. Collins AB, Schneeberger EE, Pascual MA, et al. Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol. 1999;10:2208-2214.
27. Mauiyedi S, Crespo M, Collins AB, et al. Acute humoral rejection in renal allograft recipients: II. Morphology, immunopathology, and pathologic classification. J Am Soc Nephrol. 2002;13:779-787.
28. Böhmig GA, Exner M, Habicht A, et al. Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol. 2002;13:1091-1099.
29. Nickelet V, Zeiler M, Gudat F, Thiel G, Miñatsch MJ. Detection of the complement degradation product C4d in renal allografts: diagnostic and therapeutic implications. J Am Soc Nephrol. 2002;13:242-251.
30. Haas M, Ratner LE, Montgomery RA. C4d staining of perioperative renal transplant biopsies. Transplantation. 2002;74:711-717.
31. Hidalgo LG, Sis B, Sellares J, et al. NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: evidence for NK cell involvement in antibody-mediated rejection. Am J Transplant. 2010;10:1812-1822.
32. Adam BA, Smith RN, Rosales IA, et al. Chronic antibody-mediated rejection in nonhuman primate renal allografts: validation of human histological and molecular phenotypes. Am J Transplant. 2017;17:2841-2850.
33. Afzali B, Chapman E, Racape M, et al. Molecular assessment of microcirculation injury in formalin-fixed cardiac allograft biopsies with antibody-mediated rejection. Am J Transplant. 2017;17:496-505.
34. Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation. 2000;70:887-895.
35. Jordan SC, Quartel AW, Cser LSC, et al. Posttransplant therapy using high-dose human immunoglobulin (intravenous immunoglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanisms of action. Transplantation. 1998;66:800-805.
36. Haas M, Rahman MH, Racusen LC, et al. C4d and C3d staining in biopsies of ABO- and HLA-incompatible renal allografts: correlation with histologic findings. Am J Transplant. 2006;6:1829-1840.
37. Reeve J, Bohmig GA, Eskandary F, et al. Assessing rejection-related disease in kidney transplant biopsies based on archetypal analysis of molecular phenotypes. JCI Insight. 2017;2(12). https://doi.org/10.1172/jci.insight.94197.
38. Halloran PF, Famulski KS, Reeve J. Molecular assessment of disease states in kidney transplant biopsy samples. Nat Rev Nephrol. 2016;12(9):534-548.
39. Aubert O, Loupy A, Hidalgo L, et al. Antibody-mediated rejection due to preexisting versus de novo donor-specific antibodies in kidney allograft recipients. J Am Soc Nephrol. 2017;28(6):1912-1923.
40. Venner JM, Hidalgo LG, Famulski KS, Chang J, Halloran PF. The molecular landscape of antibody-mediated kidney transplant rejection: evidence for NK involvement through CD16a Fc receptors. Am J Transplant. 2015;15:1336-1348.
41. Hayde N, Broin PO, Bao Y, et al. Increased intragraft rejection-associated gene transcripts in patients with donor-specific antibodies and normal biopsies. Kidney Int. 2014;86(3):600-609.
42. Halloran PF, Pereira AB, Chang J, et al. Potential impact of microarray diagnosis of T cell-mediated rejection in kidney transplants: The INTERCOM study. Am J Transplant. 2013;13:2352-2363.
43. Venner JM, Famulski KS, Bador D, Hidalgo LG, Chang J, Halloran PF. Molecular landscape of T cell-mediated rejection in human kidney transplants: prominence of CTLA4 and PD ligands. Am J Transplant. 2014;14:2565-2576.

How to cite this article: Haas M, Loupy A, Lefaucheur C, et al. The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell–mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am J Transplant. 2018;18:293-307. https://doi.org/10.1111/ajt.14625